HK1200449A1 - Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 - Google Patents

Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1

Info

Publication number
HK1200449A1
HK1200449A1 HK15100857.5A HK15100857A HK1200449A1 HK 1200449 A1 HK1200449 A1 HK 1200449A1 HK 15100857 A HK15100857 A HK 15100857A HK 1200449 A1 HK1200449 A1 HK 1200449A1
Authority
HK
Hong Kong
Prior art keywords
bub1
treatment
kinase inhibitors
hyperproliferative diseases
benzylindazoles
Prior art date
Application number
HK15100857.5A
Other languages
English (en)
Chinese (zh)
Inventor
．希契科克
．門格爾
．皮特
．西邁斯特
．溫內爾
．布里姆
．艾斯
．舒爾策
．費爾南德斯-蒙塔爾萬
．佩克特
．霍爾頓
．方黑內爾
．利瑙
．普羅伊塞
．格諾特
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of HK1200449A1 publication Critical patent/HK1200449A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/36—Ericaceae, e.g. azalea, cranberry or blueberry
    • A01H6/368—Vaccinium, e.g. cranberry, blueberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100857.5A 2011-10-06 2015-01-26 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 HK1200449A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184061 2011-10-06
PCT/EP2012/069562 WO2013050438A1 (en) 2011-10-06 2012-10-04 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Publications (1)

Publication Number Publication Date
HK1200449A1 true HK1200449A1 (en) 2015-08-07

Family

ID=46968229

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100857.5A HK1200449A1 (en) 2011-10-06 2015-01-26 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1

Country Status (38)

Country Link
US (3) US20140249133A1 (xx)
EP (1) EP2763982B1 (xx)
JP (1) JP6140170B2 (xx)
KR (1) KR102007056B1 (xx)
CN (1) CN103974948B (xx)
AP (1) AP3847A (xx)
AR (1) AR088449A1 (xx)
AU (1) AU2012320582B2 (xx)
BR (1) BR112014008045A2 (xx)
CA (1) CA2851037A1 (xx)
CO (1) CO6930363A2 (xx)
CR (1) CR20140161A (xx)
CU (1) CU20140043A7 (xx)
CY (1) CY1120318T1 (xx)
DK (1) DK2763982T3 (xx)
DO (1) DOP2014000062A (xx)
EA (1) EA201400412A1 (xx)
EC (1) ECSP14013284A (xx)
ES (1) ES2665036T3 (xx)
GT (1) GT201400063A (xx)
HK (1) HK1200449A1 (xx)
HR (1) HRP20180546T1 (xx)
HU (1) HUE037154T2 (xx)
IL (1) IL231591A (xx)
LT (1) LT2763982T (xx)
MX (1) MX361279B (xx)
NO (1) NO2763982T3 (xx)
PE (1) PE20141203A1 (xx)
PL (1) PL2763982T3 (xx)
PT (1) PT2763982T (xx)
RS (1) RS57099B1 (xx)
SG (1) SG11201400616YA (xx)
SI (1) SI2763982T1 (xx)
TN (1) TN2014000138A1 (xx)
TW (1) TWI588141B (xx)
UA (1) UA111754C2 (xx)
UY (1) UY34374A (xx)
WO (1) WO2013050438A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
US20150141372A1 (en) * 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
WO2014147144A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
WO2014147204A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
US20160145267A1 (en) * 2013-06-21 2016-05-26 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2916097A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
JP2016525076A (ja) * 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CA2916194A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CN105452242A (zh) * 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
CN105764893A (zh) * 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
ES2708211T3 (es) * 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
CA2961570A1 (en) * 2014-09-19 2016-03-24 Lars Barfacker Benzyl substituted indazoles
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors
WO2016042080A1 (en) * 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
EP3194381A1 (en) * 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
US10428063B2 (en) 2015-01-28 2019-10-01 Bayer Pharma Aktiengesellschaft 4H-pyrrolo[3,2-C]pyridin-4-one derivatives
JP6549735B2 (ja) * 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
WO2017102649A1 (en) * 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102048050B1 (ko) * 2019-08-29 2020-01-22 대한민국 Adb-푸비나카의 대사체 합성 방법
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
EE9900151A (et) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterotsüklüülmetüül-asendatud pürasooliderivaadid
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
CN1694708A (zh) 2002-09-10 2005-11-09 西奥斯股份有限公司 TGFβ的抑制剂
DE10244810A1 (de) * 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
WO2007065010A2 (en) * 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
EP3415515B1 (de) 2009-11-27 2019-12-25 Adverio Pharma GmbH Verfahren zur herstellung von methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ700332A (en) 2010-03-30 2017-06-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
KR101813931B1 (ko) 2010-06-30 2018-01-02 아이언우드 파마슈티컬스, 인코포레이티드 Sgc 자극제
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US20150141372A1 (en) 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
WO2014147144A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
US20160145267A1 (en) 2013-06-21 2016-05-26 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CA2916097A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CA2916194A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CN105452242A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
WO2016042080A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CA2961570A1 (en) 2014-09-19 2016-03-24 Lars Barfacker Benzyl substituted indazoles
US10350206B2 (en) 2014-09-19 2019-07-16 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as BUB1 inhibitors
EP3194381A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
PE20141203A1 (es) 2014-10-01
PL2763982T3 (pl) 2018-07-31
HUE037154T2 (hu) 2018-08-28
ES2665036T3 (es) 2018-04-24
AR088449A1 (es) 2014-06-11
AP2014007533A0 (en) 2014-03-31
CR20140161A (es) 2014-06-03
EA201400412A1 (ru) 2014-08-29
HRP20180546T1 (hr) 2018-05-04
MX361279B (es) 2018-12-03
US20190284206A1 (en) 2019-09-19
NO2763982T3 (xx) 2018-06-09
EP2763982B1 (en) 2018-01-10
WO2013050438A1 (en) 2013-04-11
CN103974948B (zh) 2017-07-28
CN103974948A (zh) 2014-08-06
US10266548B2 (en) 2019-04-23
AU2012320582A1 (en) 2014-04-17
EP2763982A1 (en) 2014-08-13
US20140249133A1 (en) 2014-09-04
CU20140043A7 (es) 2014-08-28
TW201321370A (zh) 2013-06-01
US10604532B2 (en) 2020-03-31
RS57099B1 (sr) 2018-06-29
GT201400063A (es) 2015-12-07
US20170260198A1 (en) 2017-09-14
CY1120318T1 (el) 2019-07-10
LT2763982T (lt) 2018-04-25
KR102007056B1 (ko) 2019-08-02
PT2763982T (pt) 2018-04-16
IL231591A (en) 2016-09-29
MX2014004122A (es) 2014-06-04
BR112014008045A2 (pt) 2017-04-11
UY34374A (es) 2013-05-31
AU2012320582B2 (en) 2017-06-15
JP6140170B2 (ja) 2017-05-31
JP2014531465A (ja) 2014-11-27
SI2763982T1 (en) 2018-06-29
NZ623098A (en) 2016-09-30
DK2763982T3 (en) 2018-04-23
DOP2014000062A (es) 2014-07-15
CO6930363A2 (es) 2014-04-28
CA2851037A1 (en) 2013-04-11
ECSP14013284A (es) 2014-05-31
IL231591A0 (en) 2014-05-28
TWI588141B (zh) 2017-06-21
UA111754C2 (uk) 2016-06-10
AP3847A (en) 2016-09-30
TN2014000138A1 (en) 2015-09-30
KR20140075775A (ko) 2014-06-19
SG11201400616YA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
HK1200449A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
IL229474A0 (en) Cannabinoids for use in the treatment of neuropathic pain
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
HK1223832A1 (zh) 用於癌症治療的激酶抑制劑
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211007